Navigation Links
Publication of Shire plc's Annual Report 2008

Leukodystrophy, ('GLD'))

In November 2008 Shire announced that an enzyme replacement therapy was being developed for the treatment of Krabbe disease. This program is in early development and preclinical studies.

Pharmacological Chaperone Technology

In November 2007 Shire entered into a license agreement with Amicus under which it received the rights to three compounds, PLICERA, AMIGAL and AT2220, in markets outside the US.

PLICERA (HGT-3410 for the treatment of Gaucher disease)

PLICERA is an orally-administered, small molecule pharmacological chaperone that is being developed for the treatment of Gaucher disease. PLICERA has received orphan drug designation by the European Medicines Agency ('EMEA'),which may provide it with up to ten years market exclusivity in the EU.

In March 2008 Amicus announced positive data from its Phase 2 clinical trial. Results from the Phase 2 trial support the previously reported interim findings that PLICERA was generally safe and well tolerated at all doses and increased target enzyme activity levels in a majority of patients. Shire has rights to PLICERA in markets outside the US.

AMIGAL (HGT-3310 for the treatment Fabry disease)

AMIGAL is an orally-administered, small molecule pharmacological chaperone being developed for the treatment of Fabry disease. AMIGAL has received orphan drug designation by the EMEA, which may provide it with up to ten years market exclusivity in the EU.

Amicus met with the FDA to discuss the AMIGAL development program in June 2008, and discussions are ongoing. Discussions are also ongoing with the EMEA. A final decision on the global development strategy will follow the conclusion of the discussions with both agencies. Shire has rights to AMIGAL in markets outside the US.

HGT-3510 for the treatment of Pompe disease

HGT-3510 is an orally-a

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
(Date:10/8/2015)... , October 8, 2015 ... Global Biologics and Biosimilars industry . ... "Global Biologics and Biosimilars Industry 2015 Deep Market ... Forecast" is a professional and depth research report ... ) , --> ...
(Date:10/8/2015)... 8, 2015  The ALS Association, in partnership with ... Challenge to revolutionize communication technology solutions for people living ... ALS (amyotrophic lateral sclerosis) is a progressive neurodegenerative ... and the spinal cord. Eventually, people with ALS lose ... often leads to total paralysis and death within two ...
(Date:10/8/2015)...  Sigma-Aldrich Corporation (NASDAQ: SIAL ) announced ... its Applied Diagnostics and Testing business segment has ... line with ten certified Snap-N-Spike ® solutions ... their stable-labeled internal standards. These new solution certified ... acid and native and deuterium-labeled analogs of cholic ...
(Date:10/8/2015)... ... 2015 , ... Cystic fibrosis (CF) is a genetic disease ... results in dysfunction of the lungs and the gastrointestinal (GI) tract. In CF ... very difficult to clear, blocks the airways and the glands, and creates an ...
Breaking Biology Technology:
... eResearchTechnology, Inc.,(eRT), (Nasdaq: ERES ), a ... interpretation services,announced today that Dr. Michael J. ... and Richard Baron, the Company,s Chief Financial,Officer, ... Bank 33rd Annual,Healthcare Conference at 10:10 a.m. ...
... a global endovascular device company, today reported financial,results for ... financial,guidance for 2008., As previously reported, ev3,s net ... representing a 65% increase over the same quarter of,the ... quarter of 2007. The,increase in net sales over the ...
... QSV Biologics, Ltd (QSV), a North,American based biologics ... cGMP manufacturing contract for a recombinant protein under ... at QSV,s Edmonton facility,and is intended for clinical ... and will include technology transfer, scale-up and cGMP,manufacturing., ...
Cached Biology Technology:
(Date:9/30/2015)... 30, 2015  The U.S. Court of Appeals for ... ruling in favor of Crossmatch ™, affirming the ... company Suprema and its U.S. partner Mentalix violated Section ... provision that declares it unlawful to engage in "unfair ... of Crossmatch,s patents, the 5,900,993 patent and the 7,203,344 ...
(Date:9/28/2015)... 28, 2015 CLEAR, the leading ... expedited traveler service is coming to Austin-Bergstrom ... bringing a frictionless experience, serious speed and ... "CLEAR offers our travelers an expedited security ... Jim Smith , Executive Director, Austin-Bergstrom ...
(Date:9/28/2015)... , Sept. 28, 2015 Synaptics Inc. ... interface solutions, today announced that Lenovo has selected Synaptics ... sensor, FS4202, for its latest smartphone, the Vibe P1. ... access to unlock the device and provide swift access ... The feature-rich Natural ID FS4202 sensor solution utilizes ...
Breaking Biology News(10 mins):
... MA A new study from Brigham and Women,s ... associated with how people living with chronic obstructive pulmonary ... progressive breathing disorder that limits airflow in the lungs. ... The abstract for this meta-analysis study will be ...
... by the National Institutes of Health to develop innovative ... changing environments to improve human capabilities and enhance medical ... over the next five years, subject to the availability ... of NIH,s participation in the National Robotics Initiative (NRI), ...
... climate change are posing yet another concern of growing ... some algal blooms in freshwater lakes and estuaries around ... human drinking water safety. As this nutrient enrichment, ... strains of cyanobacteria in harmful algal blooms, scientists said. ...
Cached Biology News:
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Sf21 Insect Cells (Frozen) in Max-XP Medium...
... ChipWriter Pro system, 220-240 V, uses floating ... oligonucleotides, carbohydrates, lipids, and other biomolecules onto ... This system can generate high-density arrays with ... or greater than 57,000 spots per membrane ...
Freeze 'N Squeeze DNA gel extraction spin columns use a quick freeze-and-thaw cycle and centrifugation to draw 50-23,000 bp DNA out of agarose gel slices. Supplied as 25 columns....
Biology Products: